THEON lands €70m in orders as drone and AI pivot reshapes defence-tech
THEON International, the Euronext-listed maker of night-vision and thermal-imaging systems, has announced approximately €70 million in new orders, anchored by a contract from Rheinmetall for Germany's Future Soldier programme. The announcement arrives alongside a pair of acquisitive moves that signal a deliberate pivot from pure-play optics supplier to an integrated, AI-augmented defence platform, a transformation with implications well beyond the defence procurement cycle.
The Rheinmetall order is tied to the Bundeswehr's Infanterist der Zukunft (Future Soldier) programme and draws from THEON's A.R.M.E.D ecosystem, a product portfolio centred on augmented reality applications for infantry. The company says additional option tranches may follow in the second half of the year. Cumulative order intake for Q2 reached approximately €153 million, bringing the year-to-date total to around €223 million once fully consolidated subsidiaries Kappa and Harder Digital are included. THEON reiterates guidance for an organic book-to-bill ratio above 1.0x for full-year 2026.
From optics supplier to AI-enabled platform
The more strategically significant news sits alongside the order figures. THEON last week signed a memorandum of understanding with Safran to establish a joint venture in drone technologies, majority-controlled by THEON at 51% with equal governance rights. Part of the venture's operations will be anchored in Greece, preserving what the company describes as a low-cost competitive advantage in Southern Europe. Simultaneously, THEON entered an initial agreement to acquire HGH Systèmes Infrarouges, a French counter-drone specialist, for an enterprise value of around €300 million. The deal is to be funded entirely through debt, lifting leverage to approximately 3.0x net debt to EBITDA on a pro-forma basis, before the company expects to deleverage to around 2.5x by 2027.
Philippe Mennicken, Deputy CEO and Business Development Director, described the company's positioning plainly: "THEON is positioned at the core of next-generation soldier systems. These new orders showcase customers' conviction in THEON's innovative capabilities and reflect the strong trust placed in THEON's technological expertise and execution capabilities."
The HGH acquisition is particularly telling. HGH's AI-driven software stack is cited as a source of synergies across THEON's platform-based and man-portable product lines, meaning the deal is as much a technology acquisition as a counter-drone market entry. This is a pattern now visible across European defence-tech: legacy hardware suppliers are acquiring AI software capabilities rather than building them organically, compressing the timeline between sensing, targeting and response.
The European defence-tech capital cycle
THEON's moves sit within a broader reallocation of capital that is accelerating across European defence. NATO's 2% GDP spending commitment is translating into concrete procurement pipelines, and the Bundeswehr's Future Soldier programme is one of the most visible. THEON's ability to win sequentially within that programme suggests the company has positioned itself not as a commodity component supplier but as a systems integrator, a status that typically commands both larger contract values and stickier customer relationships.
The convergence of AI software, autonomous drone platforms and electro-optical sensing is compressing what were historically distinct procurement categories. Counter-drone, night vision and AR-assisted infantry systems are increasingly parts of the same networked battlefield architecture. For cross-sector investors, this matters: defence-tech companies that can credibly span hardware sensing, AI inference and autonomous systems are attracting a different class of capital than traditional prime contractors. Private equity, sovereign wealth funds from Gulf states with their own defence modernisation programmes, and listed defence ETFs are all increasing allocations to precisely this category of converged capability.
THEON's debt-funded acquisition strategy carries execution risk at 3.0x leverage, and the Safran JV remains at MoU stage with no binding commitment yet in place. The company's Greece-anchored cost base is an asset in a European defence landscape where governments are under pressure to demonstrate domestic industrial value, but it also concentrates operational exposure in a single geography. The next meaningful data point will be whether the additional IdZ option tranches materialise in Q4 and whether the HGH transaction closes on its stated financial terms.